Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 12, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On April 11, 2006, administrators notified the company of an increase in interests in Ordinary Share ADRs for specific individuals following the re-investment of the dividend paid on April 6, 2006. The transaction price was $51.88 per ADR. The specific increases were:
- Dr. F. Calhoun: 162.891 ADRs
- Dr. J. P. Garnier: 1,593.691 ADRs
- Mr. D. Phelan: 307.374 ADRs
- Mr. D. Stout: 122.859 ADRs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is a compliance notification under Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of ADRs held by the named directors post-transaction.
- Confirm the dividend reinvestment terms for the SmithKline Beecham Mid-Term Incentive Plan.
- Check subsequent filings for any further changes in director holdings.